08. February 2012
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application for pertuzumab and granted Priority Review. more
Media: News and Press Releases
Media Releases
- February 08, 2012
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer - February 08, 2012
Roche disappointed by the actions of Illumina, Inc.'s Board of Directors - February 01, 2012
Roche in 2011: Strong results and positive outlook
Roche in the Media
|
August 31, 2011 Roche to maintain lead in targeted drugs Roche expects a new generation of drugs targeted at specific groups of patients to make up half its portfolio in 10 years, a shift that is pushing the boundaries of modern medicine. (Reuters.com) |
|
August 22, 2011 A healthy forecast for pharma Dow Jones Interview with Severin Schwan |
Services
- Contacts
- Media Archive
- Medialibrary
- Download Corporate Brochures
- RSS-Feeds
- Roche Events Podcast
- Subscribe to Roche News
- Follow Roche on Twitter
Upcoming Events
-
January 25, 2012
Media Conference Call Illumina Transaction -
Basel, Switzerland, February 01, 2012
Annual Media Conference